JP2015051973A - 挫瘡およびその他の状態を治療するためのビスファチン治療薬 - Google Patents
挫瘡およびその他の状態を治療するためのビスファチン治療薬 Download PDFInfo
- Publication number
- JP2015051973A JP2015051973A JP2014196409A JP2014196409A JP2015051973A JP 2015051973 A JP2015051973 A JP 2015051973A JP 2014196409 A JP2014196409 A JP 2014196409A JP 2014196409 A JP2014196409 A JP 2014196409A JP 2015051973 A JP2015051973 A JP 2015051973A
- Authority
- JP
- Japan
- Prior art keywords
- visfatin
- seq
- sebum
- skin
- sebaceous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/02012—Nicotinamide phosphoribosyltransferase (2.4.2.12), i.e. visfatin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Birds (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
Abstract
Description
パラフィン包埋皮膚切片の調製:実験用マウスにおいて皮膚生検を実施した。皮膚生検サンプルを4%パラホルムアルデヒド中で固定し、次にエタノールの濃度を増加させながら(50〜100%)脱水した。脱水生検サンプルをキシレン中に2回浸漬し、次にパラフィンおよびキシレンの1:1溶液中に1回、そして最後に60℃の温度で純溶融パラフィン中に3回浸漬した。次にパラフィンブロックからマイクロトームを用いて薄片を調製し、得られた切片をスライド上に載荷した。
ビスファチンは、皮膚の皮脂腺中で発現する。図1を参照されたい。皮膚内でのビスファチン発現を、組織学検査を使用して試験した。上述した材料および方法を使用して組織学検査のためにBalbCマウス(Mus musculus)由来の皮膚生検サンプルを調製した。ビスファチン免疫組織化学検査もまた上述したように実施した。
ビスファチンは、皮脂腺の内部に存在する皮脂蓄積細胞中で高度に発現する。図2を参照されたい。BalbCマウス由来の皮膚生検サンプルは、上述した材料および方法を使用して組織学検査のために調製した。ビスファチンの免疫組織化学検査およびオイルレッドO染色もまた上述のように実施した。
ビスファチンの局所投与および皮内投与は、皮脂腺の内側に局在する脂腺細胞の数を増加させる。図3を参照されたい。
ビスファチン処置は、コントロールに比して皮脂腺内の脂質蓄積を増加させる。図4を参照されたい。ビスファチン処置は、皮膚内の皮脂腺の成熟、およびコントロールに比したこれらの成熟皮脂腺による皮脂の生成もまた誘導する。図4を参照されたい。
ビスファチンアンタゴニストを用いた処置は、皮脂腺内での皮脂産生を阻害する。図5および図6を参照されたい。
ビスファチンを含む組成物は中等度から重度の乾燥皮膚を効果的に治療する。表1を参照されたい。
〔図1〕
図1は、ビスファチンの発現が皮脂腺に制限されることを示している。
2月齢のBalbCマウス由来の皮膚の組織切片を調製した。皮膚サンプルは、4%パラホルムアルデヒド中で固定し、パラフィン包埋した。皮膚切片について、抗ビスファチン抗体を用いてビスファチンを染色した(褐色)。HF(毛包)、SG(皮脂腺)、PC(末梢細胞)、CC(中心細胞)。倍率:10×および40×。顕微鏡:Nikon Eclipse 50i。
図2は、ビスファチンが皮脂腺の皮脂蓄積細胞内で発現することを示している。凍結切片は、材料および方法に記載したように2月齢のBalCマウスの皮膚から調製し、4%パラホルムアルデヒド中で固定し、ビスファチン(褐色)およびオイルレッドO(赤色)染色にかけた。倍率:10×および40×。顕微鏡:Nikon Eclipse 50i。
図3は、ビスファチンが皮脂腺内の気泡形の脂腺細胞の数を増加させることを示している。
成体BalbCマウスを4日間にわたりビスファチン(0.01μg/mL)を用いて皮内または局所的に処置した。4日後、処置された領域の皮膚切片を採取し、4%パラホルムアルデヒド中で固定し、パラフィン包埋し、皮膚切片をH&E染色した。倍率:40×。顕微鏡:Nikon Eclipse 50i。図3Aは、皮膚生検サンプルの顕微鏡写真を示している。図3Bは、皮脂腺の中心に所在する気泡形の脂腺細胞を計数し、処置の各1つについて皮脂腺中に存在する全細胞に比してそのような脂腺細胞のパーセンテージを算出することによって入手したデータを示している。
図4は、ビスファチンを用いた局所的処置が皮脂腺内での成熟および脂質蓄積を誘発することを示している。
新生仔BalbCマウスを3日間にわたりビスファチンを用いて局所的に処置した。皮膚生検は、指示した時点に採取した。図4Aでは、凍結皮膚切片を調製し、オイルレッドOを用いて染色し、ヘマトキシリンで対染色した。黒色矢印は、皮脂含有腺を示している。図4Bでは、パラフィン切片を調製し、H&E染色を行った。赤色矢印は、皮脂腺を示している。倍率:20×。顕微鏡:Nikon Eclipse 50i。
図5は、ビスファチンアンタゴニストsiRNAを用いた局所的処置が皮脂腺内での皮脂産生を抑制することを示している。
新生仔BalbCマウスは、5日間にわたりカチオン性親油性MPDYペプチドを備える3nMの結合siRNA濃度でビスファチンアンタゴニストsiRNA1およびsiRNA2の両方を用いて局所的に処置した。皮膚生検は、指示した時点に採取した。パラフィン切片を調製し、図5Aでは、ビスファチン阻害を例証するためにビスファチンについて免疫染色した。黄色矢印は、ビスファチン染色を示している。図5Bでは、凍結皮膚切片を調製し、オイルレッドOを用いて染色し、ヘマトキシリンで対染色した。黒色矢印は、皮脂含有腺を示している。図5Cでは、生検サンプルのH&E染色を実施した。赤色矢印は、成熟皮脂腺を示している。
図6は、ビスファチンアンタゴニストsiRNAを用いた局所的処置が皮脂腺内での皮脂産生を抑制することを示している。新生仔BalbCマウスを5日間にわたりカチオン性親油性MPDYペプチドを備える(図6B)、またはこのペプチドを備えない(図6A)1nM、または3nMの結合siRNA濃度でビスファチンアンタゴニストsiRNA1およびsiRNA2を用いて局所的に処置した。皮膚生検は、指示した時点に採取した。凍結切片を調製し、材料および方法において記載したようにオイルレッドOを用いて染色した。皮脂含有腺を計数し、結果は図6のグラフに要約した。
Claims (8)
- 挫創、脂漏症、脂漏性皮膚炎、皮脂嚢胞および皮脂腺過形成から選択される皮脂過剰生成状態の治療に使用するためのビスファチンアンタゴニストであって、
ここで、前記ビスファチンアンタゴニストが
a)FK−866及びAP0886から選択される少なくとも一つの化合物、又は、
b)配列番号19、20、21、22、23、24、25、26、9、10、13、14、17、及び18から選択される核酸配列を含む少なくとも一つのsiRNA、を含むビスファチンアンタゴニスト。 - 前記皮脂過剰生成状態が、挫創である前記請求項1の使用のためのビスファチンアンタゴニスト。
- 配列番号27に示すアミノ酸配列を有するアミノ末端ミリストイル化送達ペプチドとビスファチンアンタゴニストを含む医薬組成物であって、
ここで、前記ビスファチンアンタゴニストが
a)FK−866及びAP0886から選択される少なくとも一つの化合物、又は、
b)配列番号19、20、21、22、23、24、25、26、9、10、13、14、17、及び18から選択される核酸配列を含む少なくとも一つのsiRNA、を含む医薬組成物。 - さらに、水、ペトローリアムジェリー(petroleum jelly)、ワセリン(petrolatum)、鉱油、植物油、動物油、有機および無機ロウ、例えば、微結晶質、パラフィン、オゾケライトロウ、天然ポリマー、例えば、キサンタン、麦芽、タルク、ゼラチン、糖類、セルロース、コラーゲン、デンプン、もしくはアラビアゴム、合成ポリマー、アルコール、ポリオール、リン酸緩衝液、カカオ脂、乳化剤、界面活性剤から選択される薬学的に許容される担体を含む請求項3に記載の医薬組成物。
- さらに、水混和性の局所用の薬学的に許容される担体を含む請求項3に記載の医薬組成物。
- 前記水混和性担体は、リポソーム、マイクロスポンジ、マイクロスフェア、マイクロカプセル、水溶性ベースの軟膏剤、油中水型もしくは水中油型エマルジョン、及びゲル剤から選択される請求項5に記載の医薬組成物。
- 挫創、脂漏症、脂漏性皮膚炎、皮脂嚢胞および皮脂腺過形成から選択される皮脂過剰生成状態の治療における使用のための請求項3に記載の医薬組成物。
- 皮脂過剰生成状態が、挫瘡である請求項7に記載の使用のための医薬組成物。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20838609P | 2009-02-24 | 2009-02-24 | |
US61/208,386 | 2009-02-24 | ||
US26145309P | 2009-11-16 | 2009-11-16 | |
US61/261,453 | 2009-11-16 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011550698A Division JP2012518630A (ja) | 2009-02-24 | 2010-01-06 | 挫瘡およびその他の状態を治療するためのビスファチン治療薬 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016051289A Division JP2016183147A (ja) | 2009-02-24 | 2016-03-15 | 挫瘡およびその他の状態を治療するためのビスファチン治療薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015051973A true JP2015051973A (ja) | 2015-03-19 |
JP6140120B2 JP6140120B2 (ja) | 2017-05-31 |
Family
ID=42631146
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011550698A Pending JP2012518630A (ja) | 2009-02-24 | 2010-01-06 | 挫瘡およびその他の状態を治療するためのビスファチン治療薬 |
JP2014196409A Active JP6140120B2 (ja) | 2009-02-24 | 2014-09-26 | 挫瘡およびその他の状態を治療するためのビスファチン治療薬 |
JP2016051289A Pending JP2016183147A (ja) | 2009-02-24 | 2016-03-15 | 挫瘡およびその他の状態を治療するためのビスファチン治療薬 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011550698A Pending JP2012518630A (ja) | 2009-02-24 | 2010-01-06 | 挫瘡およびその他の状態を治療するためのビスファチン治療薬 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016051289A Pending JP2016183147A (ja) | 2009-02-24 | 2016-03-15 | 挫瘡およびその他の状態を治療するためのビスファチン治療薬 |
Country Status (13)
Country | Link |
---|---|
US (2) | US20100215634A1 (ja) |
EP (1) | EP2400980B1 (ja) |
JP (3) | JP2012518630A (ja) |
KR (2) | KR20130095835A (ja) |
CN (2) | CN103800903A (ja) |
AU (1) | AU2010217213B2 (ja) |
CA (1) | CA2751156A1 (ja) |
ES (1) | ES2601827T3 (ja) |
MX (1) | MX2011007970A (ja) |
NZ (2) | NZ600583A (ja) |
RU (1) | RU2011138183A (ja) |
WO (1) | WO2010097788A2 (ja) |
ZA (1) | ZA201105284B (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ545086A (en) | 2003-08-07 | 2011-06-30 | Healor Ltd | Pharmaceutical compositions and methods for accelerating wound healing |
US8367606B2 (en) * | 2005-08-29 | 2013-02-05 | Healor Ltd. | Method and compositions for prevention and treatment of diabetic and aged skin |
CN101835486B (zh) * | 2007-07-30 | 2012-12-12 | 希尔洛有限公司 | 用于治疗创伤的药物组合物以及相关方法 |
EP2504699A1 (en) * | 2009-11-27 | 2012-10-03 | MSDX, Inc. | Methods of detecting or monitoring activity of an inflammatory or neurodegenerative condition |
CA2789972A1 (en) | 2010-01-11 | 2011-07-14 | Healor Ltd. | Method for treatment of inflammatory disease and disorder |
US8673309B2 (en) * | 2011-02-11 | 2014-03-18 | Msdx, Inc. | Methods for measuring high molecular weight complexes of fibrinogen with fibronectin and fibulin-1 |
US9023399B2 (en) | 2012-11-16 | 2015-05-05 | NU Technology, LLC | Water-soluble anti-inflammatory cream with natural ingredients base |
US8613961B1 (en) | 2013-01-09 | 2013-12-24 | NU Technology, LLC | Dermatological cream with natural ingredients base |
MX2015014666A (es) | 2013-04-17 | 2016-03-01 | Pfizer | Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares. |
JP6853239B2 (ja) * | 2015-05-29 | 2021-03-31 | タギビグロウ,チャンジズ | 皮脂の過剰産生に関連する皮膚疾病を処置するためのポリペプチド及び抗体 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004521911A (ja) * | 2001-02-16 | 2004-07-22 | キングズ カレッジ ロンドン | 投薬方式 |
WO2006072809A2 (en) * | 2003-10-31 | 2006-07-13 | Robarts Research Institute | Formulations that optimize intracellular concentration of nicotinamide adenine (nad+) and methods of use to protect cells and treat diseases and conditions |
WO2008025857A2 (en) * | 2006-09-01 | 2008-03-06 | Topotarget Switzerland Sa | New method for the treatment of inflammatory diseases |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1000000A (en) * | 1910-04-25 | 1911-08-08 | Francis H Holton | Vehicle-tire. |
US4673649A (en) * | 1983-07-15 | 1987-06-16 | University Patents, Inc. | Process and defined medium for growth of human epidermal keratinocyte cells |
CA1289077C (en) * | 1984-08-13 | 1991-09-17 | Harry H. Leveen | Treatment of cancer with phlorizin and its derivatives |
US5110801A (en) * | 1984-08-13 | 1992-05-05 | Leveen Harry H | Treatment of acne |
US4843096A (en) * | 1985-06-26 | 1989-06-27 | Stiefel Laboratories, Inc. | Treatment of acne |
US4940660A (en) * | 1985-11-25 | 1990-07-10 | Wako Pure Chemical Industries | Color developing method in clinical examinations |
US4801612A (en) * | 1986-07-03 | 1989-01-31 | Regents Of The University Of California | Method of inhibiting inflammatory response |
US4833257A (en) * | 1986-07-28 | 1989-05-23 | Arizona Board Of Regents | Compositions of matter and methods of using same |
DK138888A (da) * | 1987-03-18 | 1988-09-19 | Harry H Leveen | Farmaceutisk praeparat |
US5723119A (en) * | 1989-07-28 | 1998-03-03 | Schering Corporation | Method for enhancing wound healing/repair with IL-4 |
US5145679A (en) * | 1989-10-05 | 1992-09-08 | Hinson Joan B | Topical emollient for prevention and treatment of circulatory induced lesions |
US5981606A (en) * | 1991-03-01 | 1999-11-09 | Warner-Lambert Company | Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same |
DE69229779T2 (de) * | 1991-04-19 | 1999-12-23 | Lds Technologies Inc | Konvertierbare mikroemulsionsverbindungen |
HUT67319A (en) * | 1991-08-30 | 1995-03-28 | Life Medical Sciences Inc | Compositions for treating wounds |
US5591709A (en) * | 1991-08-30 | 1997-01-07 | Life Medical Sciences, Inc. | Compositions and methods for treating wounds |
WO1993008825A1 (en) * | 1991-11-04 | 1993-05-13 | Zymogenetics, Inc. | Pdgf gel formulation |
US5948898A (en) * | 1992-03-16 | 1999-09-07 | Isis Pharmaceuticals, Inc. | Methoxyethoxy oligonucleotides for modulation of protein kinase C expression |
US5922686A (en) * | 1992-03-16 | 1999-07-13 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of protein kinase C |
IL107642A0 (en) * | 1992-11-20 | 1994-02-27 | Amgen Inc | Progenitor b cell stimulating factor |
DE69531712T2 (de) * | 1994-04-25 | 2004-07-01 | Japan Science And Technology Corp., Kawaguchi | Hybridgel, das eine biologisch aktive Substanz sekretiert |
US6028118A (en) * | 1996-08-08 | 2000-02-22 | Les Laboratoires Aeterna Inc. | Methods of using extracts of shark cartilage |
GB2304047A (en) * | 1995-08-09 | 1997-03-12 | Univ Manchester | Pharmaceutical compositions containing cytokines |
US6455247B1 (en) * | 1996-01-23 | 2002-09-24 | Board Of Trustees Of The Leland Stanford Junior University | Methods for screening for transdominant effector peptides and RNA molecules |
US5869037A (en) * | 1996-06-26 | 1999-02-09 | Cornell Research Foundation, Inc. | Adenoviral-mediated gene transfer to adipocytes |
JPH10158188A (ja) * | 1996-11-29 | 1998-06-16 | Senju Pharmaceut Co Ltd | 角膜治療用組成物 |
GB9702943D0 (en) * | 1997-02-13 | 1997-04-02 | Univ Manchester | Wound healing |
FR2773075B1 (fr) * | 1997-12-31 | 2000-05-05 | Cird Galderma | Utilisation d'activateurs de ppar-gamma en dermatologie |
US6790207B2 (en) * | 1998-06-04 | 2004-09-14 | Curon Medical, Inc. | Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract |
US6489306B2 (en) * | 1998-02-23 | 2002-12-03 | University Of South Florida | Method of intranasal gene transfer for protection against respiratory infection |
US6376467B1 (en) * | 1998-10-09 | 2002-04-23 | The Regents Of The University Of California | Use of inhibitors of protein kinase C epsilon to treat pain |
US6096288A (en) * | 1998-10-12 | 2000-08-01 | Mobil Oil Corporation | Synthesis of the cubic mesoporous molecular sieve MCM-48 |
WO2000030628A2 (en) * | 1998-11-20 | 2000-06-02 | Genentech, Inc. | Method of inhibiting angiogenesis |
US6541447B1 (en) * | 1999-09-01 | 2003-04-01 | B & M Healthcare Technologies, Inc. | Wound healing composition and method for use thereof |
JP2003523768A (ja) * | 2000-02-25 | 2003-08-12 | イミュネックス・コーポレーション | インテグリンアンタゴニスト |
WO2001076650A1 (en) * | 2000-04-06 | 2001-10-18 | University Technology Corporation | Compositions and methods for promoting wound healing |
US20060258562A1 (en) * | 2000-07-31 | 2006-11-16 | Healor Ltd. | Methods and pharmaceutical compositions for healing wounds |
GB2369572A (en) * | 2000-11-29 | 2002-06-05 | Raft Trustees Ltd | Wound treatment composition comprising insulin |
JP2002198443A (ja) * | 2000-12-26 | 2002-07-12 | Nec Corp | 半導体装置及びその製造方法 |
DE10109280A1 (de) * | 2001-02-26 | 2002-09-05 | Peter Mayser | Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen |
US20030124503A1 (en) * | 2001-12-28 | 2003-07-03 | Olivencia-Yurvati Albert H. | Pyruvate cardioplegia solutions for administration to the heart during cardiopulmonary surgery and methods of use thereof |
US20040175384A1 (en) * | 2003-12-12 | 2004-09-09 | Mohapatra Shyam S. | Protein kinase C as a target for the treatment of respiratory syncytial virus |
US20060154834A1 (en) * | 2003-07-08 | 2006-07-13 | Matthias Hauser | Products comprising an applicator and lipid and aqueous phase |
WO2005079300A2 (en) * | 2004-02-13 | 2005-09-01 | Albert Einstein College Of Medicine Of Yeshiva University | Protein kinase inhibitors and methods for identifying same |
EP1877424A4 (en) * | 2005-04-11 | 2010-09-29 | Pharmagap Inc | INHIBITORS OF PROTEIN KINASES AND USES THEREOF |
JP4730733B2 (ja) * | 2005-05-02 | 2011-07-20 | 国立大学法人京都大学 | 4型葉酸受容体の発現を指標とした制御性t細胞の検出方法、及び免疫賦活剤 |
CA2616071A1 (en) * | 2005-07-25 | 2007-02-01 | Basf Aktiengesellschaft | Dermocosmetic preparations |
CN101522627A (zh) * | 2005-08-19 | 2009-09-02 | 爱密斯菲尔科技公司 | 用于递送活性剂的环丙基化合物和组合物 |
US8367606B2 (en) * | 2005-08-29 | 2013-02-05 | Healor Ltd. | Method and compositions for prevention and treatment of diabetic and aged skin |
FR2892020B1 (fr) * | 2005-10-19 | 2007-12-21 | Seppic Sa | Composition comprenant la lauroyl proline et du laurate de sorbitan et ses utilisations dans les formulations cosmetiques et pharmaceutiques comme actif lipolytique pour une action amincissante ou anti-cellulite |
US20090010876A1 (en) * | 2007-05-21 | 2009-01-08 | The Trustees Of Columbia University In The City Of New York | Visfatin and uses thereof |
US20080312154A1 (en) * | 2007-06-15 | 2008-12-18 | Barbara Lee Peterlin | Administration of adipocytokine and adiponectin for treating headache and methods of diagnosing headache by measuring adiponectin |
WO2010011331A2 (en) * | 2008-07-24 | 2010-01-28 | The Regents Of The University Of California | Compositions and methods related to sirt1 function |
CN102186822A (zh) * | 2008-08-29 | 2011-09-14 | 顶标公司 | 新脲和硫脲衍生物 |
-
2010
- 2010-01-06 NZ NZ600583A patent/NZ600583A/xx not_active IP Right Cessation
- 2010-01-06 CN CN201310291486.4A patent/CN103800903A/zh active Pending
- 2010-01-06 CN CN2010800088741A patent/CN102325789A/zh active Pending
- 2010-01-06 KR KR1020137018539A patent/KR20130095835A/ko not_active Application Discontinuation
- 2010-01-06 EP EP10745884.6A patent/EP2400980B1/en active Active
- 2010-01-06 AU AU2010217213A patent/AU2010217213B2/en not_active Ceased
- 2010-01-06 MX MX2011007970A patent/MX2011007970A/es not_active Application Discontinuation
- 2010-01-06 CA CA2751156A patent/CA2751156A1/en not_active Abandoned
- 2010-01-06 JP JP2011550698A patent/JP2012518630A/ja active Pending
- 2010-01-06 KR KR1020117019513A patent/KR101397912B1/ko not_active IP Right Cessation
- 2010-01-06 WO PCT/IL2010/000011 patent/WO2010097788A2/en active Application Filing
- 2010-01-06 NZ NZ594067A patent/NZ594067A/xx not_active IP Right Cessation
- 2010-01-06 US US12/652,798 patent/US20100215634A1/en not_active Abandoned
- 2010-01-06 ES ES10745884.6T patent/ES2601827T3/es active Active
- 2010-01-06 RU RU2011138183/10A patent/RU2011138183A/ru not_active Application Discontinuation
-
2011
- 2011-07-18 ZA ZA2011/05284A patent/ZA201105284B/en unknown
-
2014
- 2014-08-31 US US14/474,142 patent/US9393284B2/en active Active
- 2014-09-26 JP JP2014196409A patent/JP6140120B2/ja active Active
-
2016
- 2016-03-15 JP JP2016051289A patent/JP2016183147A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004521911A (ja) * | 2001-02-16 | 2004-07-22 | キングズ カレッジ ロンドン | 投薬方式 |
WO2006072809A2 (en) * | 2003-10-31 | 2006-07-13 | Robarts Research Institute | Formulations that optimize intracellular concentration of nicotinamide adenine (nad+) and methods of use to protect cells and treat diseases and conditions |
WO2008025857A2 (en) * | 2006-09-01 | 2008-03-06 | Topotarget Switzerland Sa | New method for the treatment of inflammatory diseases |
Also Published As
Publication number | Publication date |
---|---|
WO2010097788A2 (en) | 2010-09-02 |
EP2400980A2 (en) | 2012-01-04 |
US20100215634A1 (en) | 2010-08-26 |
NZ594067A (en) | 2013-03-28 |
WO2010097788A3 (en) | 2010-10-21 |
RU2011138183A (ru) | 2013-04-10 |
MX2011007970A (es) | 2011-10-19 |
JP2016183147A (ja) | 2016-10-20 |
ZA201105284B (en) | 2012-09-26 |
KR20130095835A (ko) | 2013-08-28 |
KR101397912B1 (ko) | 2014-05-29 |
US20150065432A1 (en) | 2015-03-05 |
AU2010217213B2 (en) | 2013-05-23 |
CN102325789A (zh) | 2012-01-18 |
CA2751156A1 (en) | 2010-09-02 |
AU2010217213A1 (en) | 2011-08-04 |
ES2601827T3 (es) | 2017-02-16 |
KR20110131187A (ko) | 2011-12-06 |
EP2400980B1 (en) | 2016-08-31 |
EP2400980A4 (en) | 2013-03-27 |
WO2010097788A9 (en) | 2011-04-07 |
JP6140120B2 (ja) | 2017-05-31 |
NZ600583A (en) | 2013-08-30 |
US9393284B2 (en) | 2016-07-19 |
JP2012518630A (ja) | 2012-08-16 |
CN103800903A (zh) | 2014-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6140120B2 (ja) | 挫瘡およびその他の状態を治療するためのビスファチン治療薬 | |
US10808250B2 (en) | Fidgetin-like 2 as a target to enhance wound healing | |
JP2017527294A (ja) | Mir−29模倣物およびその使用 | |
US11697813B2 (en) | Pharmaceutical compositions and methods of use for activation of human fibroblast and myofibroblast apoptosis | |
CN101820765A (zh) | 包含雄激素受体降解(ard)增强剂的组合物和预防性或治疗性治疗皮肤病与脱发的方法 | |
JP7265992B2 (ja) | 皮膚および毛髪の治療のためのミトコンドリア組成物および方法 | |
JP2007509151A (ja) | 5α−レダクターゼ1型及び2型依存性症状を治療するための方法及び組成物 | |
US20230193276A1 (en) | Composition of drug targets and method of using thereof | |
AU2012330932B2 (en) | Pulmonary hypertension | |
Qin et al. | Cardioprotective effect of ultrasound‐targeted destruction of Sirt3‐loaded cationic microbubbles in a large animal model of pathological cardiac hypertrophy | |
EP3862429A2 (en) | Composition for extending telomere of cell and preparation method therefor | |
US10213479B2 (en) | Compounds and methods for increasing hair growth | |
JP7312993B2 (ja) | エラスチン産生促進剤及び皮膚化粧料 | |
JP2012502007A (ja) | 強皮症の治療 | |
KR20190029922A (ko) | 네프린 억제제를 유효성분으로 포함하는 피부 투과 촉진용 조성물 | |
JP4954450B2 (ja) | 弾性繊維形成の不全、欠損又は無秩序による病状に対処するための、リシルオキシダーゼのアイソフォームの活性の誘導 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150915 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151208 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160315 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160906 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170106 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170316 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170404 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170428 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6140120 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |